{
  "title": "Paper_229",
  "abstract": "Biomark Med Biomark Med 3039 bmm Biomarkers in Medicine 1752-0363 1752-0371 Taylor & Francis PMC11508994 PMC11508994.1 11508994 11508994 39360656 10.1080/17520363.2024.2404379 2404379 1 Version of Record Research Article Research Article The clinical value of combined detection of seven lung cancer-related autoantibodies in assisting the diagnosis of non-small-cell lung cancer https://orcid.org/0009-0009-9927-2148 Chen Guozhu  a Guo Ping'an  a Zhao Haiping  b Zhao Dejun  c Yang Dan *  a a The First People's Hospital of Fuyang District Laboratory Department Hangzhou 310008 China b The First People's Hospital of Fuyang District Tumor Surgery Hangzhou 310008 China c The First People's Hospital of Fuyang District Respiratory Medicine Hangzhou 310008 China * 0571 63157900 yd13738190101@163.com 3 10 2024 2024 18 20 473660 917 925 03 10 2025 03 10 2025 26 10 2024 03 10 2025 Aptara 14 9 2024 03 10 2024 15 5 2024 11 9 2024 Â© 2024 Informa UK Limited, trading as Taylor & Francis Group 2024 Aim: Methods: Results: p Conclusion: Article highlights Introduction The diagnostic efficacy of single lung cancer-related autoantibodies is low. Comparison of concentration levels of seven autoantibodies in different groups The concentrations of CAGE, GBU4-5, MAGEA1, P53, PGP9.5 and SOX2 were significantly higher than those of lung benign disease group, other malignant solid tumor group, autoimmune disease group and healthy body group, while the concentration of GAGE7 in lung cancer group was significantly higher than that of healthy body group. However, there was no significant difference between the levels and those of lung benign disease group, other malignant solid tumor group and autoimmune disease group. Efficacy of seven autoantibodies alone & in combination in the diagnosis of NSCLC The combined assay of seven autoantibodies had an AUC of 0.791, with an overall sensitivity of 60.1% and a specificity of 83.0%. It is suggested that seven lung cancer-related autoantibodies have good efficacy in the auxiliary diagnosis of NSCLC. Comparison of sensitivity between seven autoantibodies & three traditional tumor markers in the diagnosis of NSCLC The combined detection of seven autoantibodies showed consistent sensitivity in the diagnosis of different stages and pathological types of NSCLC, and the sensitivity in the diagnosis of adenocarcinoma and squamous cell carcinoma was significantly superior to CEA, NSE and CYFRA21-1. Conclusion The combined detection of seven autoantibodies has certain clinical application value. Keywords: autoantibody diagnosis non-small cell lung cancer tumor-associated antigen Hangzhou health science and technology project No. B20210500 This work was supported by Hangzhou health science and technology project (No. B20210500). pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access no pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement no pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes ",
  "metadata": {
    "Title of this paper": "The clinical value of combined detection of seven lung cancer-related autoantibodies in assisting the diagnosis of non-small-cell lung cancer",
    "Journal it was published in:": "Biomarkers in Medicine",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11508994/"
  }
}